Skip to main content

Table 3 Percentage change from baseline in lipid variables at 4 weeks (ITT population)

From: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Variable Least-squares mean percentage change from baseline to 4 weeks Difference (95% CI) p-value
Rosuvastatin 10 mg (n = 232) Atorvastatin 10 mg (n = 231)
LDL-C -47.6 -38.5a -9.1 (-11.4, -6.7) < 0.0001
TC -33.6 -27.9 -5.7 (-7.4, -4.0) < 0.0001
HDL-C 4.4 2.6 1.8 (-0.5, 4.0) NS
TG -19.2 -15.5 -3.7 (-9.5, 2.2) NS
Non-HDL-C -42.6 -35.0 -7.6 (-9.6, -5.7) < 0.0001
LDL-C/HDL-C ratio -49.3 -39.5 -9.8 (-12.2, -7.4) < 0.0001
Non-HDL-C/HDL-C ratio -44.4 -35.9 -8.5 (-10.8, -6.2) < 0.0001
TC/HDL-C ratio -35.8 -29.0 -6.7 (-8.7, -4.8) < 0.0001
Apo B -42.9 -35.3 -7.6 (-9.7, -5.6) < 0.0001
Apo A-I 2.6 0.8 1.8 (0, 3.5) 0.05
Apo B/apo A-I ratio -43.9 -35.4 -8.5 (-10.6, -6.4) < 0.0001
  1. ITT: Intention to treat, CI: Confidence interval, LDL-C: Low-density lipoprotein cholesterol, TC: Total cholesterol, HDL-C: High-density lipoprotein cholesterol, TG: Triglycerides, Apo: Apolipoprotein, NS: Not statistically significant
  2. an = 232
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840